The rise in non-fatal and fatal overdoses involving stimulants with and without opioids in the United States.
Cocaine
Opioids
United States
emergency department
overdose
stimulants
Journal
Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
31
05
2019
revised:
13
09
2019
accepted:
25
10
2019
pubmed:
9
1
2020
medline:
9
3
2021
entrez:
9
1
2020
Statut:
ppublish
Résumé
To examine trends and recent changes in non-fatal and fatal stimulant overdose rates with and without opioids to improve the descriptive characterization of the US overdose epidemic. Secondary analysis of non-fatal (2006-16) and fatal (2006-17) drug overdose trends, focusing on the most recent years of data available to examine rate changes by demographics (2015-16 for non-fatal and 2016-17 for fatal). Non-fatal drug overdoses from the Healthcare Cost and Utilization Project's Nationwide Emergency Department Sample; drug overdose deaths from the National Vital Statistics System. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, Clinical Modification/Procedure Coding System (ICD-10-CM/PCS) codes for cocaine, psychostimulants and opioids were used to classify non-fatal drug overdoses. Drug overdose deaths were identified using ICD-10 multiple cause-of-death codes for cocaine, psychostimulants, all opioids, heroin and synthetic opioids. Percentage of changes in age-adjusted non-fatal and fatal rates of cocaine and psychostimulant-involved drug overdose with and without opioids. Overall, cocaine-involved non-fatal overdose rates with an opioid increased from 2006 to 2016 [annual percentage change (APC) = 14.7], while rates without an opioid increased from 2006 to 2012 (APC = 11.3) and then remained stable (APC = -7.5). Psychostimulant-involved non-fatal rates with and without an opioid increased from 2006 to 2016 (APC = 49.9 with opioids; 13.9 without opioids). Cocaine-involved death rates with and without opioids increased from 2014 to 2017 (APC = 46.0 with opioids, 23.6 without opioids). Psychostimulant-involved death rates with opioids increased from 2010 to 2015 (APC = 28.6), with a dramatic increase from 2015 to 2017 (APC = 50.5), while rates without opioids increased from 2008 to 2017 (APC = 22.6). In 2016, 27% of non-fatal cocaine- and 14% of psychostimulant-involved overdoses included a reported opioid; 72.7% of cocaine- and 50.3% of psychostimulant-involved deaths involved an opioid in 2017. From 2015 to 2016, cocaine-involved and psychostimulant-involved non-fatal overdose rates with an opioid increased 17.0 and 5.9%, respectively; cocaine-involved and psychostimulant-involved non-fatal overdoses without opioids decreased 13.6 and increased 18.9%, respectively. Death rates involving stimulants increased with and without opioids from 2016 to 2017 (cocaine with and without opioids = 37.7 and 23.3%; psychostimulants with and without opioids = 52.2 and 23.0%). Death rates involving stimulants with synthetic opioids increased dramatically from 2016 to 2017 (1.3-2.3 per 100 000 for cocaine and 0.3-0.8 for psychostimulants). While increases in cocaine-involved deaths in the United States from 2006 seem to be driven by opioids, particularly synthetic opioids, increases in non-fatal and fatal overdoses involving psychostimulants are occurring with and without opioids.
Substances chimiques
Analgesics, Opioid
0
Central Nervous System Stimulants
0
Heroin
70D95007SX
Cocaine
I5Y540LHVR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
946-958Commentaires et corrections
Type : CommentIn
Informations de copyright
Published 2020. This article is a U.S. Government work and is in the public domain in the USA.
Références
Scholl L., Seth P., Kariisa M., Wilson N., Baldwin G. Drug and opioid-involved overdose deaths-United States, 2013-2017. Morb Mortal Wkly Rep 2018; 67: 1419-1427.
Kariisa M., Scholl L., Wilson N., Seth P. Drug overdose deaths involving cocaine and psychostimulants with abuse potential-United States, 2003-2017. Morb Mortal Wkly Rep 2019; 68: 388-395.
McCall Jones C., Baldwin G. T., Compton W. M. Recent increases in cocaine-related overdose deaths and the role of opioids. Am J Public Health 2017; 107: 430-432.
Nolan M. L., Shamasunder S., Colon-Berezin C., Kunins H. V., Paone D. Increased presence of fentanyl in cocaine-involved fatal overdoses: implications for prevention. J Urban Health 2019; 96: 49-54.
Jones C. M., Einstein E. B., Compton W. M. Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010-2016. JAMA 2018; 319: 1819-1821.
Park J. N., Weir B. W., Allen S. T., Chaulk P., Sherman S. G. Fentanyl-contaminated drugs and non-fatal overdose among people who inject drugs in Baltimore, MD. Harm Reduct J 2018; 15: 34.
Jones C. M., Christensen A., Gladden R. M. Increases in prescription opioid injection abuse among treatment admissions in the United States, 2004-2013. Drug Alcohol Depend 2017; 176: 89-95.
US Drug Enforcement Administration (USDEA). 2018 National Drug Threat Assessment. Springfield, VA: USDEA; 2018.
Seth P., Scholl L., Rudd R. A., Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants-United States, 2015--2016. Morb Mortal Wkly Rep 2018; 67: 349-358.
Agency for Healthcare Quality and Research. NEDS Overview. Healthcare Cost and Utilization Project (HCUP). Available at: www.hcup-us.ahrq.gov/nedsoverview.jsp (accessed 15 April 2019).
Seth P., Rudd R. A., Noonan R. K., Haegerich T. M. Quantifying the epidemic of prescription opioid overdose deaths. Am J Public Health 2018; 108: 500-502.
Shah A. D., Wood D. M., Dargan P. I. Survey of ICD-10 coding of hospital admissions in the UK due to recreational drug toxicity. QJM 2011; 104: 779-784.
US Drug Enforcement Administration (USDEA). DCD National Forensic Laboratory Information System: NFLIS-drug. 2017 Annual Report. Springfield, VA: USDEA; 2018.
Wang Y., Goldberger B. A., Delcher C. Florida drug-Related Outcomes and Surveillance Tracking System (FROST). Gainsville, FL: University of Florida; 2019.
National Institute on Drug Abuse (NIDA) Fentanyl. NIDA; 20 February 2019.
US Department of Health and Human Services (USDHHS). Naloxone: the Opioid Reversal Drug that Saves Lives. Washington, DC: USDHHS; 2018.
Gonzales R., Mooney L., Rawson R. A. The methamphetamine problem in the United States. Annu Rev Public Health 2010; 31: 385-398.
Shukla R. K., Crump J. L., Chrisco E. S. An evolving problem: methamphetamine production and trafficking in the United States. Int J Drug Policy 2012; 23: 426-435.
Maxwell J. C., Brecht M. L. Methamphetamine: here we go again? Addict Behav 2011; 36: 1168-1173.
Salehi M., Emadossadat A., Kheirabadi G. R., Maracy M. R., Sharbafchi M. R. The effect of buprenorphine on methamphetamine cravings. J Clin Psychopharmacol 2015; 35: 724-727.
Coffin P. O., Santos G. M., Hern J., Vittinghoff E., Santos D., Matheson T., et al. Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial. Addiction 2018; 113: 268-278.
Wu A. H., McKay C., Broussard L. A., Hoffman R. S., Kwong T. C., Moyer T. P. et al. National academy of clinical biochemistry laboratory medicine practice guidelines: recommendations for the use of laboratory tests to support poisoned patients who present to the emergency department. Clin Chem 2003; 49: 357-379.
Di Rico R., Nambiar D., Stoove M., Dietze P. Drug overdose in the ED: a record linkage study examining emergency department ICD-10 coding practices in a cohort of people who inject drugs. BMC Health Serv Res 2018; 18: 945.
Rowe C., Santos G. M., Behar E., Coffin P. O. Correlates of overdose risk perception among illicit opioid users. Drug Alcohol Depend 2016; 159: 234-239.
Moore BJ, Barrett ML. Case study: exploring how opioid-related diagnosis codes translate from ICD-9-CM to ICD-10-CM. 24 April 2017. Available at: https://www.hcup-;us.ahrq.gov/datainnovations/icd10_resources.jsp. (accessed February 28, 2019).
Slavova S., Costich J. F., Luu H., Fields J., Gabella B. A., Tarima S. et al. Interrupted time series design to evaluate the effect of the ICD-9-CM to ICD-10-CM coding transition on injury hospitalization trends. Inj Epidemiol 2018; 5: 36.
Stewart C., Crawford P. M., Simon G. E. Changes in coding of suicide attempts or self-harm with transition from ICD-9 to ICD-10. Psychiatr Serv 2017; 68: 215.
Hartel-Petri R., Krampe-Scheidler A., Braunwarth W. D., Havemann-Reinecke U., Jeschke P., Looser W. et al. Evidence-based guidelines for the pharmacologic management of methamphetamine dependence, relapse prevention, chronic methamphetamine-related, and comorbid psychiatric disorders in post-acute settings. Pharmacopsychiatry 2017; 50: 96-104.
Rich J. D., Adashi E. Y. Ideological anachronism involving needle and syringe exchange programs: lessons from the Indiana HIV outbreak. JAMA 2015; 314: 23-24.